Planning in Medical Technology

CMS, Inc., an Elekta Company, Announces First Cancer Patients Treated With Monaco(TM) Radiation Treatment Planning System

... and worldwide leader in radiation treatment planning and workflow management solutions, today ... Intensity Modulated Radiotherapy (IMRT) treatment planning system. Allegheny General Hospital in Pittsburgh, ... set of tools to make the radiotherapy planning process easier, more straightforward and ...

Children's Brain Tumor Foundation's Tissue Bank Consortium May Solve Dire Problem in Pediatric Cancer Research

... is virtually impossible," she said. Under a planning grant from the Licensing Industry ... in Chicago are participating in the planning study, which will be led by Tom Curran, PhD, ... In the project's initial phase, Dr. Curran is planning the procedures to establish consistent tissue ...

Industry Executives Finding Value in Shift of Scientific Publications

... landscape of scientific publications strategy, planning and delivery is changing with the advent ... of transparency guidelines on publications, planning and delivery - Tactics for handling ... are: - Centralization of publications strategy, planning and delivery - Trends surrounding regional ...

Hopkins Report: Focusing on Family Planning Lessens HIV Impact

... are unintended. In sub-Saharan Africa, family planning currently prevents an estimated 190,000 ... reassure both HIV-care practitioners and family planning practitioners that providing family planning to women with HIV is not difficult and not ...

Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl)

... your chance of becoming pregnant. Talk to your doctor if you are pregnant, planning to become pregnant, breastfeeding, or planning to breastfeed. When taking ACTOS with insulin or sulfonylureas, you may be ...

Large, Long-Term Study Shows Avandia Has No Increased Overall Cardiovascular Risk Compared to Other Commonly Used Diabetes Medicines

... problems while taking REZULIN(R) (troglitazone) Are pregnant or planning to become pregnant Are breastfeeding or planning to breastfeed Women taking AVANDIA should know that ...

Varian Medical Systems to Exhibit Cancer Treatment and X-ray Imaging Technologies at China Med Exhibition

... Varian to showcase products ranging from treatment planning software for radiation therapy to flat panel detectors for filmless X-ray ... medical software products, including Eclipse(TM) radiotherapy treatment planning software and ARIA(R) cancer treatment management software. The ...

CEL-SCI Corporation Releases Letter to Shareholders

... for rheumatoid arthritis. We started planning and pricing our global clinical trial designed to lead to marketing ... road. Let me share with you how we at CEL-SCI are dealing with and planning for recovery from this financial downturn. In our opinion, during such a ...

Groundbreaking Paper Publishes Long Term Results of a Successful Phase I Clinical Trial Using Autologous Neural Stem Cells to Treat Parkinson's Disease

... disease," says Levesque. Scientists at NeuroGeneration are planning a larger prospective clinical trial for Parkinson's disease. "It's our ... disease as soon as it received final approval from the FDA. It is also planning Phase I studies for multiple systems atrophy, atypical parkinsonism, ...

Mission Pharmacal Launches CitraNatal(R) Assure Prescription Prenatal Vitamin

... Prenatal vitamins are an important resource for women who are pregnant or planning to become pregnant. They provide women with the essential vitamins and ... optimize nutrition for women and their babies. Women who are pregnant or planning to conceive should consult with their healthcare provider prior to ...

GSK Believes There Is No Liver Safety Issue With AVANDIA; Responds to Public Citizen Petition

... problems while taking REZULIN(R) (troglitazone). -- Are pregnant or planning to become pregnant. -- Are breastfeeding or planning to breastfeed. Women taking AVANDIA should know that AVANDIA may increase ...

Mindset Media Study Reveals Which Independent Voters Favor Obama Vs. McCain

... personality traits, or Mindsets, consistently over-index for independents planning to vote for Obama next month: -- 120 percent more likely to be a ... for their counterparts, the following Mindsets distinguished independents planning to vote for McCain in November: -- 150 percent more likely to be a ...

GeoVax Reports Progress on Its AIDS Vaccine Technology

... Technology as an AIDS Therapeutic Human Clinical Trials in planning Stages GeoVax also announced summary data from a pilot study on ... control their HIV infections. Based on these excellent results, planning for a therapeutic trial in infected and drug treated humans has been ...

Genzyme Genetics Announces Launch of Carrier Testing and Prenatal Diagnosis for Spinal Muscular Atrophy

... inherited cause of infant mortality. This test will enable couples who are planning a pregnancy, or who are already pregnant, to determine if they are ... prenatal testing to at-risk parents; these advancements will help couples planning a pregnancy make informed decisions." The rights to perform SMN1 testing ...

Dr. Harriet Robinson Joins GeoVax Team as V.P. of R & D to Accelerate AIDS Vaccine Trials Program

... evaluating these vaccines in HIV/AIDS infected individuals are in the planning stage. GeoVax's core HIV/AIDS vaccine technologies were developed through ... immune responses in majority of human vaccine recipients -- Are in planning stage for large Phase 2 human trial scheduled for mid 2008 Safe ...

GeoVax Labs, Inc. Selected by Georgia Bio as '2008 Deal of the Year' Award Winner in Life Sciences Industry

... not be present as they will be attending a Phase 2 clinical (human) trial planning meeting for their AIDS vaccine with the HVTN (HIV Vaccine Trials Network ... immune responses in majority of human vaccine recipients -- Are in planning stage for large Phase 2 human trial scheduled for mid 2006 Georgia ...

Excellent Results Received from GeoVax's Full-Dose HIV/AIDS Vaccine Trial

... vaccine regimens started in June 2007 and are currently in process. planning of a large Phase 2 trial is underway and tentatively scheduled for a ... responses against HIV in the majority of vaccine recipients -- Are in planning stage for a larger Phase 2 human trial in 2008 For further information ...

FDA Issues Complete Response Letter for INTUNIV(TM) (guanfacine) Extended Release for the Treatment of ADHD in Children and Adolescents

... monkeys. Biol Psychiatry. 1999;46:1259-1265. 10. Jakala P, Riekkinen M, Sirvio, J, et al. Guanfacine, but not clonidine, improves planning and working memory performance in humans. Neuropsychopharmacology. 1999;2[5]:460-470. 11. INTUNIV Data on File SPD503005; Shire plc. ISS ...

R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent

... M.D., chief medical officer for Rigel. "Nonetheless, R788 is well tolerated and its side effects appear generally manageable, and we look forward to planning our Phase 3 program for R788 with a corporate partner," he added. Safety Results Tables ...

First Skin Cancer Patients Treated With Electronic Brachytherapy (eBx) At University of Wisconsin Riverview Cancer Center

... at the University of Wisconsin, Madison. Dr. Welsh collaborated with Yi Rong, Ph.D., chief medical physicist at UW Cancer Center Riverview, on the planning and delivery of the treatments. Dr. Rong will be discussing this process at the 51st annual meeting of the American Association of Physicists in ...

Pangu BioPharma, aTyr Pharma's Subsidiary in Hong Kong, Files Three Patent Applications

... Biochemistry Department at HKUST, as well as Matthew Yuen of HKUST's Research and Development group," says Professor Schimmel. Pangu BioPharma is planning to expand its drug discovery efforts in Hong Kong with continued support from HKUST and ITC. ...

GeoVax Labs, Inc. Announces Results of 2009 Annual Shareholders Meeting

... is currently ongoing and being conducted in collaboration with the U.S. National Institutes of Health-sponsored HIV Vaccine Trials Network (HVTN). planning is progressing well for initiating a therapeutic vaccination study in people already infected with HIV/AIDS. We are also utilizing our $17 million ...

Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients

... toxicity with GEMZAR treatment, sometimes fatal. Serious lung toxicity has also been reported, sometimes fatal. If you think you are pregnant, are planning to become pregnant, or are nursing, please tell your healthcare team. GEMZAR may harm your unborn or nursing baby. If you have had prior kidney ...

Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting

... first stage of our Phase 2 trial in advanced solid tumors and our late-stage clinical studies of carfilzomib in multiple myeloma, and we are actively planning a Phase 3 clinical trial in relapsed multiple myeloma patients." About Carfilzomib Carfilzomib is the first in a new class of selective, ...

Agennix Receives Fast Track Designation From FDA for Talactoferrin in Combination With Sunitinib for Renal Cell Carcinoma

... patients who have failed two or more previous therapies, and talactoferrin in combination with chemotherapy in previously untreated patients), and is planning a Phase IIb trial in patients with renal cell cancer, and Phase II trials in other cancer indications. The company has recently agreed to ...

Program Improves Language Skills in Deaf, Hard of Hearing

... hearing loss are eligible for home-based language education, assistance with audiology follow-up appointments, connections to community resources, planning for transition to preschool and other services -- all at no cost to families. The Regional Infant Hearing Programs in Ohio are funded by the Ohio ...

EPSScentral Responds to Pandemic Alert

... competency and performance, EPSScentral, together with pandemic content experts and technology partners, developed a package to address pandemic planning needs. Commencing with the SARS and Avian Flu crises over the past two years, EPSScentral developed the solution as a component of its process ...

First Candidate from Esperance's Targeted Anti-cancer Platform, EP-100, Establishes Preclinical Proof of Concept

... to existing cancer therapies such as radiation or chemotherapy." "Based on the results observed in these studies, Esperance is actively planning the initiation of a Phase 1 clinical trial of EP-100 in patients with solid cancerous tumors later this year," said Hector Alila, PhD, President of ...

NanoVibronix Receives Wound Healing Indications in Europe for its PainShield(TM) Device

... ultrasound technology. The innovative portable PainShield device for treatment of pain gained FDA clearance in October 2008. The Company is planning to launch the product in the USA during the second half of 2009. The company has also developed a unique line of catheter-based disposable ultrasound ...

New Study Suggests Cholesterol-Lowering Statins Reduce Severe Asthma Attacks that Result in Hospitalizations and Emergency Room Visits

... patients taking both a corticosteroid and a statin, nearly a one-third reduction in risk. This is the first in a series of studies that Medco is planning on asthma treatments. Future studies will examine factors that may be impeding the effectiveness of asthma medications. "Controlling asthma can ...

Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting

... indicated that the drug candidate reduced serotonin levels in humans as predicted by Lexicon's mouse models and preclinical research. Lexicon is planning to initiate a Phase 2 clinical trial of LX1032 in patients with carcinoid syndrome in the first quarter of 2009. A copy of the presentation will ...

Access Pharmaceuticals Announces Positive ProLindac(TM) Phase 2 Ovarian Cancer Clinical Trial Results

... CEO. "These data provide us with a strong incentive to continue the clinical development of ProLindac. As previously announced, we are currently planning a number of combination trials, looking at combining ProLindac with other cancer agents, such as taxol and gemcitabine, in multiple solid tumor ...

New Study Confirms That the Supports Intensity Scale Assessment is Effective in Measuring the Support Needs of People With Intellectual Disability and Making Funding Decisions

... Support Needs " is published in the January 2009 issue of the American Journal on Intellectual and Developmental Disabilities (AJIDD). The SIS is a planning tool developed by the American Association on Intellectual and Developmental Disabilities to assess needs of people with intellectual and ...

New Treatment Against Osteoarthritis: Orthokine Therapy Highly Effective Against Knee Arthritis After Two Years

... that distinguished experts have now confirmed these findings," said Dr. Peter Wehling, CEO of ORTHOGEN AG, in Düsseldorf on February 21. "We are now planning to distribute the IP-protected Orthokine technology world- wide. Orthokine is already being distributed in various EU countries through ORTHOGEN or ...

Savient Provides Update on Pegloticase BLA

... Commercialization Update "While we are eager to move the process forward as quickly as possible, the change in schedule does not impact our planning related to commercialization. The Company has always had a commercialization launch plan that parallels the FDA review process and that will be ...

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Announces FDA Filings for Paliperidone Palmitate and INVEGA(R)

... you observe any of these symptoms, talk to your healthcare professional. Inform your healthcare professional if you are pregnant or if you are planning to get pregnant while taking paliperidone. Caution should be exercised when paliperidone is administered to a nursing woman. Paliperidone may ...

Genaera Presents Promising Preclinical Data for Trodusquemine (MSI-1436) at Keystone Symposia

... obesity and diabetes," commented Jack Armstrong, President and CEO of Genaera. "We are continuing to progress the subcutaneous formulation and are planning our initial human studies with MSI-1436 via this route later this year." About Trodusquemine (MSI-1436) Trodusquemine is the first highly ...

Pulmo BioTech Inc. Announces Dual Listing on Frankfurt Borse

... outside of the United States and Canada" - Garry McCann, CEO Pulmo BioTech Inc. Pulmo BioTech's operational subsidiary, PulmoScience, is planning Phase II Human Trials for its PulmoBind product candidate for the Molecular Imaging of the vascular system of the lungs, which will follow the ...

Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference

... RNAi candidate on the basis of an E. coli delivery platform obtained from the laboratory of Patrice Courvalin at the Institut Pasteur. Cequent is planning to start a Phase I clinical trial for the indication of FAP in 2009. About Cequent Pharmaceuticals, Inc. ( www.cequentpharma.com ) An ...

Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2

... as a single agent in preclinical studies. We are delighted to have advanced CX-4945 into the clinic ahead of schedule, and we are thoughtfully planning our Phase II program in particular CK2 driven cancers." In this Phase I trial, CX-4945 will be administered to patients orally twice a day, for ...